Recent developments in liposomal drug delivery systems for the treatment of retinal diseases

Diseases of the retina cause vision loss and blindness, which have a profound impact on an individual’s quality of life. The number of therapies available to treat retinal diseases is limited. Nanoparticle (NP)-based medicines represent one strategy to expand both the number of available therapies a...

Full description

Saved in:
Bibliographic Details
Published inDrug discovery today Vol. 24; no. 8; pp. 1660 - 1668
Main Authors Urquhart, Andrew J., Eriksen, Anne Z.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2019
Subjects
Animals
Drug Delivery Systems - methods
Humans
Liposomes - chemistry
Nanoparticles - chemistry
Pharmaceutical Preparations - administration & dosage
Pharmaceutical Preparations - chemistry
Retina - drug effects
Retinal Diseases - drug therapy
Online AccessGet full text

Cover

More Information
Summary:Diseases of the retina cause vision loss and blindness, which have a profound impact on an individual’s quality of life. The number of therapies available to treat retinal diseases is limited. Nanoparticle (NP)-based medicines represent one strategy to expand both the number of available therapies and the range of retinal diseases treated. Liposomes, phospholipid vesicles that frequently contain cholesterol and/or modified surface chemistries, have already had minor success in retinal disease treatment and hold significant promise. Here, we provide a snapshot of recent research developments in liposomal drug delivery systems for retinal diseases and discuss the challenges associated with liposomal systems in the context of recent developments.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2019.04.004